Clinical Trial Update: Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing the efficacy and safety of vildagliptin versus acarbose in drug-naive adults with type 2 diabetes has completed, sponsored by Novartis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Galvus (vildagliptin)
• Precose (acarbose)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED